RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake

Revolution Medicines reported Q3 2026 results with a narrower-than-expected loss of $1.90 per share and revenues of $197.6 million, entirely from Rasonque sales following its FDA approval in late August. The drug reached over 5,000 patients in five weeks with strong reimbursement coverage. The company maintained its 2026 operating expense guidance and holds a strong cash position of $3.7 billion. European approval is pending, and multiple late-stage studies are underway for pancreatic cancer and other RAS-mutant cancers.